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Figure S1

Figure S2
A GMT Sera Fold Dilution Binding to HA-His 10 1 10 2 10 3 10 4 10 5 10 6 10 7 0 1 2 3 4 A450 Group A 10 1 10 2 10 3 10 4 10 5 10 6 10 7 Group B 10 1 10 2 10 3 10 4 10 5 10 6 10 7 Group C 1 2 3 4 5 6 Anti-Env Figure S2 . Characterization of vaccine-elicited neutralizing responses reveals cross-neutralization in multiple subjects, related to Figure 2. (A) Geometric mean IgG titers (GMT, ±SD; n = 6) are shown above for Post 4 to Post 6 immunizations, as measured by His-capture ELISA to the different WT immunogens. Below, anti-His binding responses directed against HA-His protein from Post 6 sera, as measured by ELISA with animal numbers from each group as indicated. The sera were also assessed against 16055 NFL trimer with the average response for each group shown as a gray dashed line for reference. (B) Post 6 sera neutralizing titers (ID50, sera-fold dilution at which 50% neutralization is achieved) are indicated against the panel of viruses used to derive the sequential Env trimer immunogens. (C) Crossneutralization of purified IgG (IC50, µg/ml) from the Post 5 time point against a panel of representative (tier 2) clinical HIV-1 isolates across different clades. (D) The trimer-specific PGT145 bNAb served as a positive control for the solidphase adsorption assay using a 16055 NFL TD CC+ trimer affinity column to deplete Env binding Abs prior to neutralization assessment against virus TRO.11. A PBS-immersed (media) blank lectin column was used as a negative control. (E) Differential adsorption of virus entry. Left, PGT145 or VRC13 (CD4bs-directed bNAb) were pre-incubated at a fixed concentration with culture medium (no inhibitor) or titrating amounts of WT or the CD4bs knockout (368/474) 16055 gp120 TriMut proteins prior to assessing neutralization against virus TRO.11 as negative and positive controls. Right, purified IgG from C3 anti-sera (Post 5) was pre-incubated at a fixed concentration with medium or titrating amounts of the TriMut proteins prior to assessing neutralization against viruses 16055 and X2278. All assays were performed at least twice with representative data shown.
Figure S3
A E N-Glycan Dependence VRC01 Table S5 . (A) Fourier shell correlation (FSC) and orientation angle distribution of C3 symmetric reconstruction of BG505 NFL CC+ in complex with E70 Fab. (B) E70 Fab interactions with N234 glycan are primarily with the D1 arm. A complete Man9 glycoform is modeled (data supported sugars colored green; idealized model sugars colored dark red) to demonstrate that the D2 and D3 arms can be accommodated but do not contribute to the Ab epitope. Glycan N276 (grey) below is not involved in binding. (C) Additional E70 peptide contacts include C3 and V5 of gp120. (D) Amino acid contacts within the E70 epitope with conservation shown as a percentage. (E) Env binding angle comparison between E70 and non-VRC01 class Abs CH103 (PDB 4JAN) and CH235 (5F9W). (F) Overlap of contact residues between E70, VRC01, and PGV19. Asparagine residues marked with a star (*) denote that the contact is with a sugar molecule and not the amino acid side chain. Analysis based on a 4.0 Å distance cutoff between Fab and gp120 (VRC01 based on PDB 5FYK; PGV19 based on PDB 6B0N). Residues listed are of BG505 NFL TD CC+ (HXBc2 numbering). (G) Differences in glycan interactions between CD4bs-directed mAbs. VRC01 based on PDB 5FYK. PGV19 based on PDB 6B0N. Figure S6 . Epitope analysis and high resolution cryoEM structure of 1C2 bound-Env trimer reveals complex interface recognition, related to Figure 6 and Tables S5-S6. (A) ~3.9 Å resolution reconstruction of 16055 NFL TD 2CC+ trimer in complex with 1C2 Fab, colored by local resolution according to the key. One Fab is boxed for reference. To the right, the Fourier shell correlation (FSC) and orientation angle distribution of C3 symmetric reconstruction of 16055 NFL TD 2CC+ in complex with 1C2 Fab are shown. (B) Crystal structure of unliganded 1C2 Fab. Heavy (green) and light (cyan) chains are shown in ribbon representation. The CDRs are highlighted. (C) Comparison of the N88 glycan conformation between the 1C2-bound 16055 NFL TD 2CC+ structure (green) and other published HIV-1 trimer structures with near atomic resolution (< 4.5 Å) that have modeled N88 glycans (n = 42). Subset comparisons between 35O22-bound Env trimers, FP-directed mAbs (vFP20.01, PDB 6CDE; vFP16.02, PDB 6CDI; VRC34, PDB 5I8H ) with the N88 from the PGT128-bound Env (PDB 5ACO) shown as a reference, and gp120 Env-only structures are presented. (D) Neutralization sensitivity of gp120:gp41-directed mAbs against a panel of JRFL N-glycan mutants around the interface. VRC01 (CD4bs-directed) is included as a negative control. IC50 (µg/ml) values are shown. (E) 1C2 binding to cell surface expressed WT BG505 Env compared to that with the N88 and N625 PNGS genetically removed (∆N88/N625), as assessed by FACs. PGT145 and 2G12 binding were included as trimer expression controls. (F) Comparison of Env (gp120, light grey; gp41 dark grey) recognition by 1C2 (blue) and the vaccine-elicited FP targeting mAb DFPH-a.15 (orange; PDB 6N1W). Interaction with a single protomer is shown for clarity with the FP highlighted in red. Figure S7. 1C2 neutralization breadth is broader than the human bNAb 3BC315, related to Figure 6 . Neutralization IC50 (µg/ml) values shown for 1C2 and 3BC315 against a diverse 208-virus panel. Table S1 . Site-specific glycan analysis of N-glycan deleted trimers compared to WT, related to Figure 1 . Percentage point differences in glycan abundances for glycan-deleted constructs compared to WT. A decrease in glycan abundance greater than 10 percentage points is highlighted in increasing shades of red, whereas an increase in abundance is highlighted in green. Knocked-out glycans are highlighted in blue. 
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